Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,751 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,318)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07671417 | Imaging Study in Metastatic Clear Cell RCC. | recruiting | Early Phase 1 | 10 | RayzeBio, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | recruiting | Early Phase 1 | 30 | University of ArizonaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04665947 |
| First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer |
| active not recruiting |
| Early Phase 1 |
| 30 |
| University of California, DavisOTHER |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer(TIDE) | not yet recruiting | Early Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04005690 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | recruiting | Early Phase 1 | 90 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05141643 | Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | recruiting | Early Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04861077 | Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) | recruiting | Early Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05415709 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | active not recruiting | Early Phase 1 | 35 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05733715 | Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma | recruiting | Early Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03943173 | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06586047 | Breast Cancer PSMA PET | recruiting | Early Phase 1 | 30 | Ahmad ShariftabriziOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05464810 | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer | recruiting | Early Phase 1 | 40 | Emory UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05041153 | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | not yet recruiting | Early Phase 1 | 6 | Royan InstituteOTHER_GOV | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06824363 | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu | recruiting | Early Phase 1 | 34 | University of California, IrvineOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05852041 | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | recruiting | Early Phase 1 | 40 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06813898 | An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial | recruiting | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04494113 | Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy | active not recruiting | Early Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02210117 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | active not recruiting | Early Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06122896 | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals | recruiting | Early Phase 1 | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06937567 | CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05365893 | PHL Treatment in Pancreatic Cancer | active not recruiting | Early Phase 1 | 20 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03594630 | Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer | recruiting | Early Phase 1 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06637306 | Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer | recruiting | Early Phase 1 | 15 | Rima PatelOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06318871 | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | active not recruiting | Early Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07553767 | Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | not yet recruiting | Early Phase 1 | 156 | Ningbo No.2 HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02744053 | DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer | active not recruiting | Early Phase 1 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07487402 | Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02659241 | Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Early Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05108428 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | active not recruiting | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06435351 | Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy | recruiting | Early Phase 1 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07089940 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Early Phase 1 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | recruiting | Early Phase 1 | 48 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | active not recruiting | Early Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07352345 | Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 150 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06220214 | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer | recruiting | Early Phase 1 | 30 | Alison StopeckOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07340424 | A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. | recruiting | Early Phase 1 | 15 | Xiaorong SunOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07341360 | Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei(Pseudovax) | recruiting | Early Phase 1 | 10 | Oslo University HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05336266 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma(KetoROCX) | active not recruiting | Early Phase 1 | 28 | Andrew Hendifar, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03511196 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | active not recruiting | Early Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06008275 | Neratinib in Combination With Ruxolitinib in Patients With mTNBC | recruiting | Early Phase 1 | 20 | Baylor Research InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04857684 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | active not recruiting | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201064 | A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 12 | Guangdong ProCapZoom Biosciences Co., Ltd.INDUSTRY | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06700070 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | recruiting | Early Phase 1 | 12 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials